Joshua Ruch, an insider at GeneDx Holdings Corp (WGS), sold 29,731 shares of the company on November 23, 2025, at a price of $158.40 per share, resulting in a total transaction value of $4.71 million. Following this sale, Ruch retains 29,731 shares in the company.
GeneDx Holdings Corp, which operates as a health intelligence company, focuses on exome and genome testing through its subsidiary, GeneDx, LLC. The firm, headquartered in Stamford, Connecticut, employs approximately 1,000 full-time staff and went public on September 4, 2020. It specializes in pediatric and rare disease diagnostics, offering a range of genomic testing options designed to provide personalized health insights and improve healthcare efficiencies.
As of November 18, 2025, GeneDx has a market capitalization of $4.0 billion and a trailing twelve-month price-to-earnings ratio of 1,922.81, with earnings per share reported at $0.06. Upcoming earnings are anticipated on July 27, 2026, with an estimated EPS of $0.04 and revenue of $125.7 million.
Insider transactions, such as this sale, can reflect various motivations including personal financial needs or diversification strategies. While significant selling may raise questions among investors, it is essential to consider the broader context of insider activity and not rely solely on isolated transactions. Monitoring patterns of insider buying and selling can provide additional insights into executive sentiment and company health.